Neuropsychiatrie s.r.o. — Clinical Trial Site

13 Registered trials

6 Currently recruiting

Organisation

Neuropsychiatrie s.r.o.

Location

Prague 6, Czechia

Identifier

ORG-100044150

Address

Terronska 580/19, Bubenec, 160 00, Czechia

Departments

---
N/A
NA
Neurology
Neuropsychiatrie s.r.o
Neuropsychiatrie s.r.o.

Clinical trials at this site (13)

Search interface

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521711-39-00 Lewy body Dementia psychosis (LBDP) 5 2026-05-17
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Mild to moderate Alzheimer’s Disease 5 2025-11-18
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521710-25-00 Lewy Body Dementia Psychosis (LBDP) 4 2025-12-04
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Agitation Associated with Alzheimer’s Disease 5 2025-11-28
A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacod… Recruiting

2024-517957-29-00 Mild Cognitive Impairment (MCI) 4 2025-04-02
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended

2024-514680-26-00 Agitation Associated with Alzheimer’s Dementia 4 2025-07-17
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Schizophrenia 5